| Company Name: |
Zhejiang Huida Biotech Co., Ltd.
|
| Tel: |
0571-89903022 18679456698 |
| Email: |
zilong@hizyme.com |
| Products Intro: |
Product Name:RIDR-PI-103
CAS:2581114-71-6
Purity:>=98% Package:1mg
|
|
| | Acetamide, 2-amino-N-[5-amino-2-[3-[4-(4-morpholinyl)pyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-2-yl]phenoxy]phenyl]- Basic information |
| | Acetamide, 2-amino-N-[5-amino-2-[3-[4-(4-morpholinyl)pyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-2-yl]phenoxy]phenyl]- Chemical Properties |
| density | 1.427±0.06 g/cm3(Predicted) | | storage temp. | 4°C, away from moisture and light | | pka | 12.82±0.70(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | Acetamide, 2-amino-N-[5-amino-2-[3-[4-(4-morpholinyl)pyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-2-yl]phenoxy]phenyl]- Usage And Synthesis |
| Uses | RIDR-PI-103 is a reactive oxygen species (ROS)-induced agent release proagent with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103). Doxorubicin and RIDR-PI-103 shows a synergistic effect in MDA-MB-361 and MDA-MB-231 cells to inhibit cancer cell proliferation[1][2]. | | References | [1] Mishra R, et al. Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. Int J Mol Sci. 2021;22(4):2088. Published 2021 Feb 19. DOI:10.3390/ijms22042088
[2] Rosalin Mishra, et al. Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-10-04. |
| | Acetamide, 2-amino-N-[5-amino-2-[3-[4-(4-morpholinyl)pyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-2-yl]phenoxy]phenyl]- Preparation Products And Raw materials |
|